gemcitabine has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bernardini, N; Bocci, G; Collecchi, P; Danesi, R; Del Tacca, M; Fioravanti, A; Orlandi, P | 1 |
| Budman, DR; Calabro, A | 1 |
| Budman, DR; Calabro, A; Lesser, M; Rosen, L | 1 |
3 other study(ies) available for gemcitabine and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Fluvastatin synergistically enhances the antiproliferative effect of gemcitabine in human pancreatic cancer MIAPaCa-2 cells.
Topics: 5'-Nucleotidase; Animals; Antimetabolites, Antineoplastic; Apoptosis; Cell Line, Tumor; Cell Proliferation; Deoxycytidine; Deoxycytidine Kinase; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Gemcitabine; Genes, ras; Humans; Immunoblotting; Immunohistochemistry; Indoles; Male; Mevalonic Acid; Mice; Mitogen-Activated Protein Kinase 1; Mutation; Pancreatic Neoplasms; Phosphorylation; Proto-Oncogene Proteins p21(ras); rho GTP-Binding Proteins | 2005 |
Zoledronic acid (Zometa) enhances the cytotoxic effect of gemcitabine and fluvastatin: in vitro isobologram studies with conventional and nonconventional cytotoxic agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Cell Line, Tumor; Cytoplasm; Deoxycytidine; Diphosphonates; DNA Fragmentation; Drug Antagonism; Drug Synergism; Epirubicin; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Prostatic Neoplasms; Zoledronic Acid | 2006 |
Identification of unique synergistic drug combinations associated with downexpression of survivin in a preclinical breast cancer model system.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Caspase 3; Cell Line, Tumor; Deoxycytidine; Docetaxel; Down-Regulation; Doxorubicin; Drug Screening Assays, Antitumor; Fatty Acids, Monounsaturated; Female; Fluvastatin; Gemcitabine; Humans; Hydroxamic Acids; Indoles; Inhibitor of Apoptosis Proteins; Panobinostat; Receptor, ErbB-2; Survivin; Taxoids | 2012 |